OAK BROOK, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the fourth quarter and fiscal year ended December 28, 2025. Fourth Quarter 2025 Performance Highlights (vs. Fourth Quarter 2024): Total revenue of $185.7 million, an increase of 0.6% or $1.1 millionSame-restaurant sales decrease of -3.3%Operating income of $10.3 million, a de ...

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharm ...

ZEELAND, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today announced that its Board of Directors recently declared a quarterly cash dividend of $0.12 (12 cents) per share that will be payable April 22, 2026, to shareholders of record of the common stock at the close of business on April 8, 2026. About the CompanyFounde ...

Core Viewpoint - Kyverna Therapeutics has appointed Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors, enhancing its leadership team as the company advances towards commercialization of its cell therapies for autoimmune diseases [1][3]. Group 1: Board Appointments - Sravan K. Emany will serve as the Audit Committee Chair, succeeding Dan Spiegelman, who has stepped down from the Board [2]. - Andrew Miller, Ph.D. is recognized for his extensive experience in clinical development and product approval, which will support Kyverna's growth [1][3]. Group 2: Leadership Experience - Sravan Emany has a strong background in financial leadership, currently serving as CFO of Beam Therapeutics, and has held significant roles in investment banking, including at Bank of America and Goldman Sachs [3][4]. - Dr. Andrew Miller was the Founder and President of R&D at Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion in 2024, and has been recognized as one of Time Magazine's 100 Next Generation Leaders [4]. Group 3: Company Overview - Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, with its lead candidate, miv-cel, showing potential to change treatment paradigms for B-cell-driven autoimmune diseases [5]. - The company is advancing its neuroimmunology franchise with completed and ongoing registrational trials for conditions such as stiff person syndrome and generalized myasthenia gravis [5].

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ...

Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment  Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care set ...

Core Insights - Clene Inc. is focused on developing treatments for neurodegenerative diseases, particularly ALS, through its investigational drug CNM-Au8, with key regulatory and clinical milestones anticipated in 2026 [1][2] Financial Position - The company completed an oversubscribed registered direct offering of over $28 million in January 2026, providing sufficient cash to fund operations into the fourth quarter of 2026 [4][7] - Additional financing tranches totaling over $22 million are structured to align with NDA acceptance and FDA approval milestones, expected to support operations into 2027 [4] Regulatory Steps and Clinical Milestones - Clene has engaged with the FDA regarding CNM-Au8, with an in-person Type C meeting scheduled by the end of Q1 2026 to discuss data submitted in late 2025 [5][7] - The company plans to submit a New Drug Application (NDA) for CNM-Au8 via an accelerated regulatory pathway in Q2 2026, with potential FDA acceptance and PDUFA date issuance in the second half of 2026 [5][7] Clinical Data and Efficacy - CNM-Au8 has shown prolonged survival in ALS patients, with a median life expectancy of 2-4 years post-diagnosis, and demonstrated statistically significant reductions in mortality risk and clinical worsening [6][8] - The treatment has also shown favorable safety and tolerability, with no serious adverse events reported across over 1,000 patient years of treatment [9] Future Trials - A confirmatory Phase 3 RESTORE-ALS trial is planned to begin later in 2026 to further evaluate the survival benefit of CNM-Au8 [10] Broader Pipeline - CNM-Au8 is also being explored for potential benefits in multiple sclerosis (MS) and Parkinson's disease, with plans to finalize Phase 3 clinical trial designs for MS in 2026 [12]

Core Insights - Artelo Biosciences, Inc. is advancing its clinical-stage pharmaceutical programs with positive human data and upcoming clinical catalysts, focusing on treatments for cancer, pain, and other conditions [1] Business Highlights - Successful completion of a Phase 1 study for ART26.12, showing a favorable safety profile and predictable pharmacokinetics, with plans to initiate a multiple ascending dose study in Q3 2026 [2] - Positive interim Phase 2 results for ART27.13, demonstrating improvements in body weight, lean body mass, and physical activity in patients with cancer anorexia-cachexia syndrome [3] - Received favorable regulatory guidance from the UK MHRA for ART12.11, with plans to initiate human clinical studies in H1 2027 [4] Clinical Progress - ART26.12 has shown sustained analgesic effects comparable to naproxen without tolerance in preclinical models, positioning it as a non-opioid alternative for pain management [5] - ART27.13 has received a Notice of Allowance from the European Patent Office, extending patent protection through December 2041, which has increased partner interest in its development [5] - ART12.11 has demonstrated robust antidepressant-like activity in preclinical studies, with plans for first-in-human studies early next year [5] Financial Results - Research and development expenses for FY 2025 were $5.4 million, down from $6.0 million in FY 2024 [6] - General and administrative expenses increased to $6.0 million in FY 2025 from $4.1 million in the previous year [6] - The net loss for FY 2025 was $12.9 million, or $12.52 per share, compared to a net loss of $9.8 million in FY 2024 [6] - Cash and investments totaled $0.6 million as of December 31, 2025 [6] Product Information - ART26.12 is a lead FABP5 inhibitor aimed at treating chemotherapy-induced peripheral neuropathy, with a favorable safety profile and dosing flexibility [8] - ART27.13 is a cannabinoid receptor agonist targeting cancer-related anorexia and cachexia, showing a mean weight gain of over 6% in the top dose group compared to a 5% loss in the placebo group [9][10] - ART12.11 is a proprietary cocrystal composition of CBD and TMP, with enhanced pharmacokinetics and plans for clinical studies in 2026 [11]

Core Viewpoint - Erasca, Inc. has received a patent for ERAS-4001, a pan-KRAS inhibitor, providing intellectual property protection until at least 2043, which strengthens its position in the RAS-driven cancer market [1][2] Group 1: Intellectual Property and Pipeline - The newly issued U.S. patent enhances the ERAS-4001 program and supports the company's diversified intellectual property strategy in RAS-driven cancers [2] - The patent protection for ERAS-4001 extends through at least 2043, with additional patents pending, providing a robust long-term IP foundation [2] - Initial Phase 1 monotherapy data for ERAS-0015 is expected in the first half of 2026, while data for ERAS-4001 is anticipated in the second half of 2026 [1] Group 2: Product Details - ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor currently being evaluated in the BOREALIS-1 Phase 1 trial for patients with KRAS-mutant solid tumors [3] - Preclinical studies show ERAS-4001 has favorable potency against KRAS G12X mutations and wildtype amplifications, with no activity against HRAS or NRAS wildtype proteins [3] - ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS-1 Phase 1 trial, demonstrating favorable safety and tolerability, with early data showing responses in multiple patients [4] Group 3: Company Overview - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [5] - The company's mission is to "erase cancer" through novel therapies and combination regimens targeting the RAS/MAPK pathway [5]

SAN FRANCISCO and OAKLAND, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, has completed a successful dispatching season of a first-of-its-kind distributed power plant partnership with Pacific Gas and Electric Company (PG&E). More than 1,000 Sunrun customers’ storage-plus-solar systems exported energy to alleviate local grid constraints, with the goal of helping PG&E avoid or defer distribution upgrades ...